Skip to main content
Publications
Blonde L, Raccah D, Lew E, Meyers J , Nikonova E, Ajmera M, Davis KL , Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin . Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Webb S, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM , Signorovitch JE, McLeod L , Maldonado M, Zgliczylski W, De Block C, Portocarrero-Ortiz L, Gadelha MR. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease . Eur J Endocrinol. 2014 Jul;171(1):89-98. doi: 10.1530/EJE-13-1013
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043